NRC-AN-019
目录号: A13562
Bcr-Abl 抑制剂
NRC-AN-019 是一种口服酪氨酸激酶抑制剂(TKI),针对 Bcr-Abl 蛋白酪氨酸激酶。NRC-AN-019 在抑制血管生成潜力和 MDAMB231 以及 HTB20/BT474 细胞的增殖方面更为有效。
| Discription | NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells. |
|---|
| 目录号 | A13562 |
|---|---|
| 分子式 | C25H17F6N5O |
| 分子量 | 517.431 |
| CAS号 | 879507-25-2 |
| SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4 |
| 其他名称 | AN019, AN 019, NRC-an-019 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2